C oronary artery disease (CAD) remains one of the major causes of death. Recent data indicate that classic risk factors and novel risk markers account for a large proportion of disease risk. 1, 2 Despite these considerable advances, it remains apparent that the underlying causes of CAD are multifactorial and involve a complex interplay between acquired and inherited risk factors. The advent of genome-wide association (GWA) studies led to the identification of several genetic loci that associate with the risk of CAD. [3] [4] [5] [6] [7] The majority of these associations are located in genomic regions for which functional understanding is lacking. 8 Consequently, there exists a substantial gap in our understanding about how these single-nucleotide polymorphisms (SNPs) affect the pathophysiological mechanisms through which the loci contribute to disease. Variation in gene expression appears to be an important intermediate step underlying susceptibility of complex diseases. 9 -15 The abundance of a gene transcript can be directly modified by polymorphisms; thus, transcript abundance mediated by genetic variation either alone or in combination with environmental factors might be considered as a quantitative trait that can be mapped. 15 When combined with GWA data, the analysis of the transcriptome can help to clarify and categorize effects of CAD-associated SNPs on gene expression (eSNPs).
Clinical Perspective on p 412
In the present study, a GWA case-control study in 5031 individuals followed by 2 stages of replication and a final meta-analysis of 59 789 cases and control subjects was performed. This approach led to the identification of a novel CAD susceptibility locus on chromosome 10q23.31, LIPA. Additionally, eQTL analysis, using a data set of global monocytic gene expression, revealed a strong effect of LIPA eSNPs on LIPA transcript levels, and LIPA transcript levels in turn showed association to prevalent cardiovascular risk factors and phenotypes of subclinical disease.
Methods

Study Design
A GWA study using the Genome-Wide Human SNP 6.0 Array (Affymetrix, Santa Clara, CA) was conducted to discover SNPs associated with CAD in the CADomics study (Coronary Artery Disease and Genomics), a case-control study of CAD (2078 CAD cases and 2953 control subjects). Replication of SNPs was performed in 2 steps. SNPs associated with CAD in the discovery stage at a threshold probability value of Ͻ10 Ϫ3 , entered the first replication stage (in silico replication in 9487 cases and 30 171 control subjects of the following studies with European ancestry: CHARGE, GerMIFS I, GerMIFS II, MIGen, WTCCC-CAD, PennCATH, and MedStar). On the basis of a threshold probability value of Ͻ10 Ϫ4 in the pooled analysis of the discovery and the first replication stage, SNPs were selected for the second replication stage (wet laboratory replication in 9863 cases and 5237 control subjects of the following studies with European ancestry: ECTIM, AngioLueb, GoKard, LURIC, popgen, and MORGAM). A final meta-analysis was performed in 21 428 cases and 38 361 control subjects. SNPs passing a conservative threshold of statistical significance at PϽ5ϫ10 Ϫ8 in the final meta-analysis were further evaluated for their association to global gene expression in 1494 apparently healthy, population-based samples from the Gutenberg Heart Express (GHSExpress) study for identifying SNPs (eSNPs) that affect gene expression (eQTL transcripts). Finally, we explored eSNPs and respective eQTL transcripts for their association with cardiovascular risk factors and phenotypes of subclinical disease. The study design is depicted in Figure 1 .
Description of Study Samples
CADomics is a case-control study including the hospital-based catheter laboratory AtheroGene Registry 16 and the population-based Gutenberg-Heart Study (GHS). For the present analysis, individuals with angiographically proven CAD (stenosis Ͼ50% in 1 major coronary artery), nearly 60% presenting with acute myocardial infarction, were included as cases, and individuals without a history of myocardial infarction and/or history of CAD were taken from the population-based cohort as control subjects. The GHSExpress study is a subsample of GHS participants-who served as control subjects in the CADomics study-from which RNA was directly extracted from monocytes isolated from fresh blood samples. Characteristics of the CADomics and the GHSExpress study samples are provided in Table 1 and Online-only Data Supplement Table I . Further detailed description of the studies is provided in the Online-only Data Supplement Materials. Descriptions of the studies used for replication stages are provided in the Online-only Data Supplement Materials and Online-only Data Supplement Table II .
Genotyping
For CADomics, genomic DNA was isolated from buffy coats of EDTA plasma samples as described elsewhere. 17 Genotyping was conducted on the Affymetrix Genome-Wide Human SNP 6.0 Array; quality control on sample and SNP level was performed according to standardized criteria. 18 Genotyping was performed in individuals of European descent only. A detailed description of genotyping methods and quality control is provided in the Online-only Data Supplement Materials. In total, 5031 samples and 608 247 SNPs were included in the analyses. Online-only Data Supplement Table III Figure 1 . Study design of the CADomics Study. The study consisted of a discovery GWA stage, followed by 2 stages of replication (in silico and wet laboratory) in independent study samples and a final meta-analysis. SNPs with genome-wide significance (PϽ5ϫ10
Ϫ8
) were further explored for their association with global gene expression (eSNPs, eQTLs) in monocytes and cardiovascular risk factors. Statistical evidence for association was combined across several stages, using a final meta-analysis.
provides information on genotyping platforms and methods used for all replication studies.
Global Gene Expression
Isolation of total RNA and analysis of gene expression were performed as recently described. 15 In brief, total RNA was isolated from monocytes of 1606 participants of the GHSExpress Study and hybridized to Illumina HT-12 v3 BeadChips (Illumina Inc, San Diego, CA). Arrays were quantile-normalized and transformed using the arcsinh function. After quality control, 14 027 expressed RefSeq transcripts in 1494 samples were used for eQTL analyses. Detailed description of the methods is given in the Online-only Data Supplement Materials.
Cardiovascular Risk Factors and Phenotypes of Subclinical Disease
eQTL transcripts and eSNPs were investigated for associations with prevalent cardiovascular risk factors (LDL-and HDL-cholesterol, triglycerides, diabetes mellitus, HbA 1c , and systolic and diastolic blood pressure) and phenotypes of subclinical disease (flowmediated vasodilation and carotid macroangiopathy). Methods of risk factor measurements and descriptions of phenotype assessment are described in the Online-only Data Supplement Materials.
Statistical Methods
In the discovery GWA analysis, association of CAD with SNPs was tested with the use of an additive genetic model in a logistic regression. In both replication steps (in silico and wet laboratory replication), fixed-effects meta-analysis using inverse-variance weighting was performed with the R package MetABEL. 19 Associations between SNPs and transcripts were investigated with the use of the median test, 20 with a significance level of probability Ͻ10 Ϫ8 , corresponding to a probability value of Ͻ10 Ϫ12 in an ANOVA 20 for the samples that passed quality control for both genotype and expression data. SNPs located within 500 kb of either the 5Ј or 3Ј end of the associated gene were considered as cis-acting SNPs; otherwise, they were called to act in trans. Only associations of transcripts without SNPs in probe sequences are reported. 21 Associations of eSNPs and eQTL transcripts with cardiovascular risk factors were analyzed using logistic and linear regression for qualitative and quantitative traits, respectively. Triglycerides and HbA 1c were log-transformed before analysis.
Probability values were corrected for multiple testing with the use of false discovery rate 22 and a significance level of 0.05.
All analyses were performed using R, version 2.10.1 (http://www.r-project.org).
Results
Discovery GWA Study, Replication, and Final Meta-Analysis
The discovery GWAS revealed 950 SNPs that were associated with CAD at a level of PϽ10 Ϫ3 in the 2078 CAD cases and 2953 population-based control subjects of the CADomics study. The strongest association was observed for the previously described region at 9p21. All 950 SNPs were selected for in silico replication in 7 independent case-control studies (9487 cases and 30 171 control subjects). Only SNPs with PϽ10 Ϫ4 in the pooled analysis of CADomics and the in silico replication studies were selected for wet laboratory replication (Online-only Data Supplement Table IV ). For loci with several CADassociated SNPs, tagSNPs were selected for replication. A total of 20 SNPs was genotyped in 6 additional replication studies including 9863 cases and 5237 control subjects. Results of the discovery GWA study, both replication stages and the subsequent meta-analysis finally including 21 428 cases and 38 361 control subjects, are presented in Table 2 .
As expected, the chromosome 9p21.3 locus revealed the strongest association with CAD in the meta-analysis of all 14 studies included (lead SNP rs1333049: Pϭ7.12ϫ10 Ϫ58 ; OR, 1.27; 95% CI, 1.23 to 1.31; Online-only Data Supplement Figure I ). A locus on chromosome 10q23.31, so far not known to be associated with CAD, also reached genome-wide significance in the meta-analysis ( Figure 2A ; rs1412444: Pϭ3.71ϫ10 Ϫ8 ; OR, 1.1; 95% CI, 1.07 to 1.14; rs2246833: Pϭ4.35ϫ10 Ϫ8 ; OR, 1.1; 95% CI, 1.06 to 1.14).
Identification of eSNPs and eQTL Transcripts
All SNPs that reached genome-wide significance (Table 2) were further tested for association with monocytic transcripts in cis (SNPs located within 500 kb of either the 5Ј or 3Ј end of the associated gene) and trans. 2B and Table 3 ). Both LIPA SNPs were in strong linkage disequilibrium (r 2 ϭ0.985), and for both SNPs, the CAD risk allele (T) was associated with higher LIPA expression. Figure  2C displays regional plots for the association of LIPA eSNPs and eQTL transcripts in relation to CAD. A "platform validation" was conducted in 119 monocytic samples, using quantitative reverse-transcriptase-polymerase chain reaction analyses, and the association of LIPA SNPs with LIPA transcripts was successfully replicated (rs1412444: Pϭ3.87ϫ10 Ϫ8 , rs2246833: Pϭ1.52ϫ10 Ϫ8 ; see also Onlineonly Data Supplement Figure II) .
The CAD-associated SNPs in the 9p21.3 region, rs1333049, rs7865618, and rs7044859, showed no association to global monocytic gene expression.
Association of LIPA eSNPs and eQTL Transcripts With Cardiovascular Risk Factors and Phenotypes of Subclinical Atherosclerosis
To explore potential mechanisms mediating the genetic risk, the relationship of LIPA mRNA transcript and the respective LIPA eSNPs rs1412444 and rs2246833 to cardiovascular risk factors (LDL-and HDL-cholesterol, triglycerides, diabetes mellitus, HbA 1c , and systolic and diastolic blood pressure) and subclinical atherosclerotic disease (endothelial function measured and carotid macroangiopathy) was investigated. Detailed results are provided in Table 4 . Elevated LIPA expression was significantly associated with lower HDL-cholesterol levels (Pϭ2.5ϫ10 Ϫ3 ) and impaired endothelial function measured by flow-mediated vasodilation (Pϭ4.04ϫ 10 Ϫ3 ), whereas associations with higher levels of LDL-cholesterol and triglycerides did not reach statistical significance. In contrast, no significant association between LIPA eSNPs and any cardiovascular risk factor was observed.
eSNPs Located in Known CAD Loci
In addition to SNPs identified in our analysis, we performed an eQTL analysis for SNPs previously reported to be associated with CAD and/or myocardial infarction, [3] [4] [5] 7, 23 but not found in our analysis. Of 26 SNPs investigated (Online-only Data Supplement Table V), only 3 SNPs in 2 loci were associated with eQTL transcripts (Table 3 ). In our data, the locus on chromosome 1p13 (represented by SNPs rs599839 and rs629301) revealed a strong association with PSRC1 transcripts with the risk allele for both SNPs associated with decreased transcript levels of PSRC1. For the second locus, the risk allele of SNP rs6725887, located within the WDR12 gene on chromosome 2q33, was associated with decreased FAM117B transcript levels (located close to WDR12). The association of these eSNPs and eQTL transcripts with cardiovascular risk factors and phenotypes of subclinical disease was further analyzed (Table 4 ). Significant associations between increased PSRC1 transcript levels and lower LDL-cholesterol levels (Pϭ8.2ϫ10 , respectively), and an improved endothelial function (Pϭ2.2ϫ10 Ϫ4 ) were observed. As previously reported 3,4,24 the risk alleles of eSNPs rs599839 and rs629301 were robustly associated with increasing LDL cholesterol levels (Pϭ3.96ϫ10 Ϫ4 and Pϭ3.93ϫ10
Ϫ4
). In addition, the risk alleles were associated with the extent of atherosclerotic plaques (Pϭ1.44ϫ10 Ϫ3 and Pϭ1.23ϫ10
Ϫ3
). No significant association was found for FAM117B transcript levels and respective eSNPs with cardiovascular risk factors and phenotypes of subclinical disease.
Discussion
A GWA study for CAD was performed, and loci identified were further evaluated to explore their potential functional relevance by (1) testing functionality of genetic variants in relation to gene expression and (2) correlating expression levels with CAD risk factors and disease precursors such as endothelial function and carotid atherosclerosis.
In addition to the previously known locus on chromosome 9p21, our study identified the LIPA gene on chromosome 10q23 as a novel CAD susceptibility locus (Pϭ3.71ϫ10
Ϫ8
and Pϭ4.35ϫ10 Ϫ8 for SNPs rs1412444 and rs2246833). In the subsequent eQTL analysis, LIPA genotypes displayed a strong association with LIPA transcripts (Pϭ1.31ϫ10 Ϫ96 and
Pϭ3.97ϫ10 Ϫ96 , respectively), with the CAD risk allele being associated with higher LIPA expression. Further, elevated LIPA expression itself was related to lower HDL-cholesterol levels and impaired endothelial function, a precursor of CAD.
In humans, the LIPA gene encodes lysosomal acid lipase (LAL). 25, 26 LAL hydrolyzes cholesteryl esters and triglycerides delivered to the lysosome. If LAL is missing and/or not active, trigylcerides and cholesteryl esters accumulate in the cell, resulting in foam cell formation and as a consequence in atherosclerotic plaque. 27 Mutations in the LIPA gene are the cause of the cholesteryl ester storage disease and Wolman disease. 28, 29 Patients with these diseases also have premature cardiovascular disease. 29 Residual LAL activity determines the severity of clinical symptoms, with Wolman patients having the lowest residual activity. 30 Our data demonstrate that the LIPA CAD risk allele is associated with increased LIPA expression. Increased intrinsic LIPA expression might enhance intracellular release of fatty acids and cholesterol through the lysosomal route, 27 possibly explaining the association of the risk allele with impaired endothelial function, a precursor of atherosclerosis. 31 Furthermore, increased LIPA expression is expected to be associated with increased LAL activity. Unesterified cholesterol is a hallmark of atherosclerotic lesions. 32 In fact, cholesteryl ester hydrolysis has been shown to be a critical step in the enzymatic modification of LDL particles in the intima, conferring the ability to activate complement to LDL and rendering them proatherogenic. 33, 34 Thus, the risk allele could increase the generation of enzymatically modified LDL and free cholesterol in the arterial intima, thereby promoting foam cell formation, complement activation, and an inflammatory process.
The significant association of the LIPA eSNPs rs1412444 and rs2246833 with CAD, their strong association with expression and the relation between transcript levels, and subclinical disease in apparently healthy individuals strongly supports a causal role for the LIPA gene in atherosclerosis.
We also studied the relationship of previously published loci to gene expression, cardiovascular risk factors, and Results from eQTL analysis of CAD-associated SNPs (PϽ5ϫ10 Ϫ8 ), based on results of the present CADomics study and SNPs of previously published loci for CAD. SNPs located within 500 kb of either the 5Ј or 3Ј end of the associated gene were considered as cis-acting; otherwise, they were called to act in trans.
*The corresponding published tagSNP for rs629301 is rs646776. 
Ϫ2
Table shows the strength of association by ␤ estimates or ORs with the corresponding 95% CI and uncorrected P values.
*P values that remain significant after correction for false discovery rate.
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phenotypes. The association of the risk alleles on the 1p13 locus with decreased PSRC1 transcript and increased LDLcholesterol levels had been reported previously. 24 Further, our data showed significant association for 1p13 eSNPs and PSCR1 transcript levels with blood pressure and endothelial function, indicating that this genetic risk locus might act through these CAD risk factors. In human liver, the 1p13 locus affects transcript levels of CELSR2, PSRC1, and SORT1, with the strongest regulatory effect for SORT1. 3, 24 Further, in a recent study by Musunuru et al, 35 liver-specific transcriptional regulation of the SORT1 gene by C/EBP transcription factors was shown, and SORT1 has been nominated as the causal gene at the 1p13 locus for LDL-cholesterol and myocardial infarction. However, as previously reported by our group, 15 SORT1 was not cis-regulated in our data set of global monocytic gene expression, suggesting a different mechanism of transcript regulation of the 1p13 locus in monocytes, and does not exclude PSRC1 as an important contributor to lipid levels and coronary artery disease. Some limitations merit consideration. Cases comprise individuals with severe coronary atherosclerosis documented by angiography and myocardial infarction. Gene expression studies were performed in monocytes. Hence, other cell types might yield different results. Finally, we did not test expression profiles in cases. However, because patients are receiving CAD treatment, medication probably would severely modify expression patterns.
Overall, the use of genome-wide SNP data and the monocyte transcriptome (GHSExpress, http://genecanvas.ecgene.net/uploads; for review, see Reference 15) 15 led to the identification of a novel locus potentially relevant for the development of CAD. The respective eSNPs strongly affected LIPA gene expression, and the LIPA expression level itself was related to subclinical disease as assessed by vascular endothelial function. The consistency of our results between genetic variants, LIPA expression level, and disease precursor identifies LIPA as an attractive research candidate for follow-up functional studies, also emphasized by the association between LAL deficiency and the rare cholesteryl ester storage disease and Wolman disease.
